Lataa...

Metabolic reprogramming by N‐acetyl‐seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease

BACKGROUND AND PURPOSE: ACE inhibitors (ACEIs) and AT(1) receptor antagonists (ARBs) are first‐line drugs that are believed to reduce the progression of end‐stage renal disease in diabetic patients. Differences in the effects of ACEIs and ARBs are not well studied and the mechanisms responsible are...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Pharmacol
Päätekijät: Srivastava, Swayam Prakash, Goodwin, Julie E., Kanasaki, Keizo, Koya, Daisuke
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393199/
https://ncbi.nlm.nih.gov/pubmed/32352559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15087
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!